APA (7e ed.) Bronvermelding

Leask, A., Xu, S., Renzoni, E., Bou-Gharios, G., du Bois, R., Abraham, D., & Black, C. (2005). Bosentan alleviates the pro-fibrotic phenotype of lung scleroderma fibroblasts: Implications for treatment of scleroderma.

Chicago (17e ed.) Bronvermelding

Leask, A., S. Xu, E. Renzoni, G. Bou-Gharios, R. du Bois, D. Abraham, en C. Black. Bosentan Alleviates the Pro-fibrotic Phenotype of Lung Scleroderma Fibroblasts: Implications for Treatment of Scleroderma. 2005.

MLA (9e ed.) Bronvermelding

Leask, A., et al. Bosentan Alleviates the Pro-fibrotic Phenotype of Lung Scleroderma Fibroblasts: Implications for Treatment of Scleroderma. 2005.